TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs
Brief Summary: Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body.


Options:
A: Arm Label: once daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Arm Label: twice daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Intervention Type: DRUG; Name: colchicine; Assigned to Arm(s): once daily dosage schema of colchicine, twice daily dosage schema of colchicine
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rilonacept 160 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: rilonacept 160 mg | Arm Label: Open-Label rilonacept 160 mg; Type: OTHER; Interventions: Drug: rilonacept 160 mg | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): rilonacept 160 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): Open-Label rilonacept 160 mg
C: Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Kineret | Arm Label: Kineret (Anakinra); Type: EXPERIMENTAL; Interventions: Drug: Kineret | Intervention Type: DRUG; Name: Kineret; Assigned to Arm(s): Kineret (Anakinra), Vehicle
D: Arm Label: crFMF: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: crCMF: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: HIDS/MKD: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: HIDS/MKD: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: TRAPS: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: TRAPS: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): HIDS/MKD: 150 mg, TRAPS: 150 mg, crFMF: 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): HIDS/MKD: placebo, TRAPS: placebo, crCMF: placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs
Brief Summary: Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body.


Options:
A: Arm Label: Canakinumab; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): Canakinumab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rilonacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rilonacept 160 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: rilonacept 160 mg | Arm Label: Open-Label rilonacept 160 mg; Type: OTHER; Interventions: Drug: rilonacept 160 mg | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): rilonacept 160 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): Open-Label rilonacept 160 mg
D: Arm Label: crFMF: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: crCMF: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: HIDS/MKD: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: HIDS/MKD: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: TRAPS: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: TRAPS: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): HIDS/MKD: 150 mg, TRAPS: 150 mg, crFMF: 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): HIDS/MKD: placebo, TRAPS: placebo, crCMF: placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Management of Osteoarthritis: A Tailored, Telephone-based Intervention
Brief Summary: The purpose of this study is to examine whether a telephone-based self-management intervention improves pain, physical function, and other outcomes among veterans with osteoarthritis of the hip or knee.


Options:
A: Arm Label: Real mobilization-with-movement (MWM); Type: EXPERIMENTAL; Interventions: Other: Real mobilization-with-movement (MWM) | Arm Label: Sham mobilization-with-movement (MWM); Type: SHAM_COMPARATOR; Interventions: Other: Sham mobilization-with-movement (MWM) | Intervention Type: OTHER; Name: Real mobilization-with-movement (MWM); Assigned to Arm(s): Real mobilization-with-movement (MWM) | Intervention Type: OTHER; Name: Sham mobilization-with-movement (MWM); Assigned to Arm(s): Sham mobilization-with-movement (MWM)
B: Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Physical Therapy for knee OA | Arm Label: Cognitive Behavioral Therapy for Pain; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Pain CBT-P | Arm Label: Enhanced Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Treatment as Usual | Intervention Type: PROCEDURE; Name: Physical Therapy for knee OA; Assigned to Arm(s): Physical Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Pain CBT-P; Assigned to Arm(s): Cognitive Behavioral Therapy for Pain | Intervention Type: OTHER; Name: Enhanced Treatment as Usual; Assigned to Arm(s): Enhanced Treatment as Usual
C: Arm Label: Kinesio taping group; Type: EXPERIMENTAL; Interventions: Other: Taping application | Arm Label: Non specific taping; Type: SHAM_COMPARATOR; Interventions: Other: Taping application | Intervention Type: OTHER; Name: Taping application; Assigned to Arm(s): Kinesio taping group, Non specific taping
D: Arm Label: Health Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Arm Label: Usual Medical Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Osteoarthritis Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Self-Management | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Self-Management; Assigned to Arm(s): Osteoarthritis Self-Management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Management of Osteoarthritis: A Tailored, Telephone-based Intervention
Brief Summary: The purpose of this study is to examine whether a telephone-based self-management intervention improves pain, physical function, and other outcomes among veterans with osteoarthritis of the hip or knee.


Options:
A: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Intervention; Assigned to Arm(s): Arm 2
B: Arm Label: Health Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Arm Label: Usual Medical Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Osteoarthritis Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Self-Management | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Self-Management; Assigned to Arm(s): Osteoarthritis Self-Management
C: Arm Label: Patient education; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Patient education and supervised exercise | Arm Label: Patient education and supervised exercise; Type: EXPERIMENTAL; Interventions: Procedure: Patient education and supervised exercise | Intervention Type: PROCEDURE; Name: Patient education and supervised exercise; Assigned to Arm(s): Patient education, Patient education and supervised exercise
D: Arm Label: Patient education programme; Type: EXPERIMENTAL; Interventions: Other: Patient education programme | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient education programme; Assigned to Arm(s): Patient education programme

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose
Brief Summary: Rotavirus disease is the most common cause of gastroenteritis and dehydration in young children worldwide. The global public health burden has prompted the development of a human rotavirus vaccine against rotavirus disease by GlaxoSmithKline Biologicals. This pre-registration study is undertaken to provide immunogenicity, reactogenicity and safety data for the vaccine when used in Indian infants aged approximately 8 weeks at the time of the first dose.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1
B: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose
Brief Summary: Rotavirus disease is the most common cause of gastroenteritis and dehydration in young children worldwide. The global public health burden has prompted the development of a human rotavirus vaccine against rotavirus disease by GlaxoSmithKline Biologicals. This pre-registration study is undertaken to provide immunogenicity, reactogenicity and safety data for the vaccine when used in Indian infants aged approximately 8 weeks at the time of the first dose.


Options:
A: Arm Label: Liq_A Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Liq_B Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Liq_C Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Lyo Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: HRV PCV-free liquid vaccine; Assigned to Arm(s): Liq_A Group, Liq_B Group, Liq_C Group | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Lyo Group
B: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: V260 with staggered EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with staggered EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Arm Label: V260 with concomitant EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with concomitant EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Intervention Type: BIOLOGICAL; Name: V260; Assigned to Arm(s): V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: Placebo to V260; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: DTaP; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI
D: Arm Label: Co-administration Group; Type: EXPERIMENTAL; Interventions: Biological: Squarekids, Biological: Rotarix | Arm Label: Staggered Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Squarekids, Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Squarekids; Assigned to Arm(s): Co-administration Group, Staggered Group | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Co-administration Group, Staggered Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose
Brief Summary: Rotavirus disease is the most common cause of gastroenteritis and dehydration in young children worldwide. The global public health burden has prompted the development of a human rotavirus vaccine against rotavirus disease by GlaxoSmithKline Biologicals. This pre-registration study is undertaken to provide immunogenicity, reactogenicity and safety data for the vaccine when used in Indian infants aged approximately 8 weeks at the time of the first dose.


Options:
A: Arm Label: Bivalent OPV 2 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 2 week interval | Arm Label: Bivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 4 week interval | Arm Label: Monovalent OPV 2week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 2 week interval | Arm Label: Monovalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 4 week interval | Arm Label: Trivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 2 week interval; Assigned to Arm(s): Bivalent OPV 2 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 4 week interval; Assigned to Arm(s): Bivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 2 week interval; Assigned to Arm(s): Monovalent OPV 2week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 4 week interval; Assigned to Arm(s): Monovalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Trivalent OPV 4 week interval; Assigned to Arm(s): Trivalent OPV 4 week interval
B: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1
D: Arm Label: Rotavirus Vaccine at age 6 & 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 10 & 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 6,10,&14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Human Rotavirus Vaccine; Assigned to Arm(s): Rotavirus Vaccine at age 6 & 10 weeks, Rotavirus vaccine at age 10 & 14 weeks, Rotavirus vaccine at age 6,10,&14 weeks

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LEVP2005-1/Part A: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) for the Treatment of HAE in Acute Attacks
Brief Summary: The study objective was to determine the safety and efficacy of C1INH-nf for the treatment of acute HAE attacks.


Options:
A: Arm Label: C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): C1INH-nf | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo
B: Arm Label: C1INH-nf First, then Placebo; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf), Drug: Placebo (saline) | Arm Label: Placebo First, then C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf), Drug: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): C1INH-nf First, then Placebo, Placebo First, then C1INH-nf | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): C1INH-nf First, then Placebo, Placebo First, then C1INH-nf
C: Arm Label: BCX4161; Type: ACTIVE_COMPARATOR; Interventions: Drug: BCX4161 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CSL312 (low); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med/high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Intervention Type: BIOLOGICAL; Name: Factor XIIa antagonist monoclonal antibody; Assigned to Arm(s): CSL312 (high), CSL312 (low), CSL312 (med), CSL312 (med/high) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India
Brief Summary: The primary purpose of this study is to estimate the efficacy of a two-dose regimen of the oral killed bivalent cholera vaccine when administered to individual residing in a cholera-endemic area in India.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rBS-WC vaccine | Intervention Type: BIOLOGICAL; Name: rBS-WC vaccine; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: bivalent killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: bivalent killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Shanchol; Type: EXPERIMENTAL; Interventions: Biological: Shanchol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): Shanchol | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Shanchol Dose-interval Group 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Cholera Vaccine | Arm Label: Shanchol Dose-Interval Group 2; Type: EXPERIMENTAL; Interventions: Biological: Adjusted Dose Oral Cholera Vaccine | Intervention Type: BIOLOGICAL; Name: Oral Cholera Vaccine; Assigned to Arm(s): Shanchol Dose-interval Group 1 | Intervention Type: BIOLOGICAL; Name: Adjusted Dose Oral Cholera Vaccine; Assigned to Arm(s): Shanchol Dose-Interval Group 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India
Brief Summary: The primary purpose of this study is to estimate the efficacy of a two-dose regimen of the oral killed bivalent cholera vaccine when administered to individual residing in a cholera-endemic area in India.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Killed bivalent whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli Placebo | Intervention Type: BIOLOGICAL; Name: Killed bivalent whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Injection | Arm Label: TA-CD Vaccination; Type: EXPERIMENTAL; Interventions: Drug: TA-CD Vaccination | Intervention Type: DRUG; Name: TA-CD Vaccination; Assigned to Arm(s): TA-CD Vaccination | Intervention Type: OTHER; Name: Placebo Injection; Assigned to Arm(s): Placebo injection
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: bivalent killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: bivalent killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2

Answer: D